How does DPH N's PE Ratio compare to its peers?

DPH N is expensive based on its Price-To-Earnings Ratio (105.6x) compared to the peer average (28.7x).

How does DPH N's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

DPH N is expensive based on its Price-To-Earnings Ratio (105.6x) compared to the Global Pharmaceuticals industry average (24.2x).

What is DPH N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate DPH N's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of DPH N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DPH N (MX$858.69) is trading above our estimate of [[fair value]] (MX$425.81)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Dechra Pharmaceuticals (BMV:DPH N) - Stock Price, News & Analysis

DPH N Stock Overview

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. More details

DPH N fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Rewards

Earnings are forecast to grow 21.21% per year

Risk Analysis

Shares are highly illiquid

Debt is not well covered by operating cash flow

Profit margins (5.5%) are lower than last year (11.4%)

Shareholders have been diluted in the past year

Dechra Pharmaceuticals PLC Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.7b

Dong-E-E-JiaoLtd

SZSE:000423

CN¥36.4b

Ono Pharmaceutical

TSE:4528

JP¥820.8b

Haisco Pharmaceutical Group

SZSE:002653

CN¥38.4b

Price History & Performance

Summary of all time highs, changes and price drops for Dechra Pharmaceuticals
Historical stock prices
Current Share Price	UK£858.69
52 Week High	UK£863.85
52 Week Low	UK£740.83
Beta	0.71
11 Month Change	0%
3 Month Change	n/a
1 Year Change	2.09%
33 Year Change	34.09%
5 Year Change	n/a
Change since IPO	28.77%

Recent updates

Shareholder Returns

	DPH N	MX Pharmaceuticals	MX Market
7D	0%	-1.3%	-0.3%
1Y	2.1%	-19.3%	-4.0%

Return vs Industry: DPH N exceeded the MX Pharmaceuticals industry which returned -15% over the past year.

Return vs Market: DPH N underperformed the MX Market which returned 3.7% over the past year.

Price Volatility

Is DPH N's price volatile compared to industry and market?
DPH N volatility
DPH N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.1%
10% least volatile stocks in MX Market	2.7%

Stable Share Price: DPH N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DPH N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	1,998	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.

Dechra Pharmaceuticals PLC Fundamentals Summary

How do Dechra Pharmaceuticals's earnings and revenue compare to its market cap?
DPH N fundamental statistics
Market cap	Mex$95.37b
Earnings (TTM)	Mex$902.94m
Revenue (TTM)	Mex$16.37b

105.6x

P/E Ratio

5.8x

P/S Ratio

Is DPH N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DPH N income statement (TTM)
Revenue	UK£726.80m
Cost of Revenue	UK£312.20m
Gross Profit	UK£414.60m
Other Expenses	UK£374.50m
Earnings	UK£40.10m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

Sep 04, 2023

Earnings per share (EPS)	0.35
Gross Margin	57.04%
Net Profit Margin	5.52%
Debt/Equity Ratio	61.8%

How did DPH N perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

125%

Payout Ratio

DPH N Stock Overview

Rewards

Risk Analysis

Dechra Pharmaceuticals PLC Competitors

BMV:LAB B

Mex$24.7b

SZSE:000423

CN¥36.4b

TSE:4528

JP¥820.8b

SZSE:002653

CN¥38.4b

Price History & Performance

Recent News & Updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Announces Executive Changes

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Non-Executive Chairman recently bought Mex$2.6m worth of stock

Investor sentiment improved over the past week

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Investor sentiment deteriorated over the past week

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Less than half of directors are independent

Upcoming dividend of UK£0.29 per share

Less than half of directors are independent

Non-Executive Director recently bought Mex$178k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Less than half of directors are independent

Board Member recently sold Mex$27m worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

CEO, MD & Executive Director recently sold Mex$279m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Non-Executive Director recently bought Mex$712k worth of stock

Independent Non Executive Director recently sold Mex$3.5m worth of stock

Shareholder Returns

Price Volatility

About the Company

Dechra Pharmaceuticals PLC Fundamentals Summary

105.6x

5.8x

Earnings & Revenue